Pensacola, FL, and Philadelphia, PA, March 10, 2026 - Ametris, a global digital health solutions provider transforming real-world patient data into validated clinical evidence, and Signant Health, a leader in evidence generation for modern clinical trials, today announced a strategic partnership to advance drug development in central nervous system (CNS) disorders and other complex therapeutic areas. By combining Ametris’ best-in-class wearable digital health technology (DHT) with Signant Health’s industry-leading electronic clinical outcome assessment (eCOA) platform, the collaboration provides biopharma sponsors with a unified solution that combines clinician- and patient-reported outcomes with objective movement and physical activity data, offering sponsors a more complete view of patient function and treatment effects in central nervous system (CNS) trials.
Clinical trials in CNS disorders benefit from multiple complementary approaches to capture meaningful changes in patient function. Traditional clinical outcome assessments (COAs) provide essential insights into how patients feel and function in their daily lives - the outcomes that matter most to patients and regulators. CNS studies, especially those in diseases with heterogeneous or slowly progressive trajectories such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions, can benefit from combining COAs with continuous objective measures to better detect subtle changes that may emerge between traditional assessment timepoints and strengthen evidence of treatment effects across multiple dimensions of patient functioning.
At the same time, DHTs, including wearables, sensors and AI-enabled assessment platforms, are rapidly emerging as valuable tools for clinical research. These technologies enable objective, continuous, and real-time measurement of motor, cognitive, speech, and behavioral parameters collected within the patients’ natural environments, providing rich insights into disease progression and treatment response.
Signant Health’s Rater Station® eCOA platform addresses key endpoint reliability challenges associated with subjective clinician assessments by driving standardized assessment administration and scoring, reducing scoring errors, minimizing inter-rater variability, and improving signal detection in complex clinical trials. Together with Ametris’ wearable DHT solutions, the combined offering delivers comprehensive patient insights by integrating scheduled patient assessments with continuous movement and physical activity data for studies involving complex and sensitive endpoints.
"Integrating COA data with continuous movement and physical activity monitoring is valuable for advancing drug development in complex CNS disorders," said Christine Guo, PhD, Chief Scientific Officer at Ametris. "By combining patient assessments captured through eCOA with continuous sensor-based data from wearable DHTs, we can provide sponsors with complementary perspectives on how patients are functioning over time. This integrated approach helps sponsors evaluate disease progression and treatment effects with greater confidence in these trials."
"Clinical outcome assessments remain the gold standard for understanding what matters most in CNS trials - how patients feel and function in their daily lives," said Dawie Wessels, MBChB, Chief Medical Officer at Signant Health. "Our partnership with Ametris allows us to offer sponsors a solution that preserves the essential patient voice captured through eCOA while adding continuous physical activity and movement context. This is particularly valuable in CNS studies where sponsors need multiple lines of evidence to demonstrate meaningful treatment benefit. Together, we're giving sponsors the tools to build stronger, more comprehensive efficacy cases."
About Ametris
Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support to simplify every phase of a clinical trial—from study design to submission. Backed by two decades of experience and a collaborative approach, Ametris empowers research teams to run smarter trials, reduce patient burden, and accelerate therapeutic innovation.
About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. signanthealth.com